Back to top
more

Regeneron Pharmaceuticals (REGN)

(Real Time Quote from BATS)

$822.32 USD

822.32
278,546

-7.11 (-0.86%)

Updated Nov 6, 2024 11:52 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

AstraZeneca (AZN) Divests Migraine Drug Rights Beyond Japan

by Zacks Equity Research

AstraZeneca PLC (AZN) has inked a deal to sell the global rights of migraine treatment drug Zomig (zolmitriptan) outside Japan to Grunenthal, a German pharmaceutical company.

    Acorda Presents Phase III Data on PD Candidate CVT-301

    by Zacks Equity Research

    Acorda Therapeutics, Inc. (ACOR) presented data from a phase III study SPAN-PD, evaluating its late stage candidate CVT-301 (levodopa inhalation powder) at the International Congress of Parkinson's Disease and Movement Disorders (MDS).

      Pfizer's (PFE) Tafamidis Gets Fast Track Status in the U.S.

      by Zacks Equity Research

      Pfizer Inc. (PFE) has been granted with fast track status by FDA for treating patients with transthyretin cardiomyopathy (TTR-CM).

        Amgen Files for Repatha in the U.S., EU for Expanded Use

        by Zacks Equity Research

        Biotech major, Amgen, Inc. (AMGN) announced that it submitted regulatory applications for its PCSK9 inhibitor, Repatha in both the U.S. and EU.

          Regeneron Announces Positive Data on Carcinoma Candidate

          by Zacks Equity Research

          Regeneron Pharmaceuticals and partner Sanofi announced positive results related to its experimental candidate, REGN2810, a checkpoint inhibitor targeting PD-1 in patients with advanced cutaneous squamous cell carcinoma (CSCC).

            John Blank headshot

            Don't Be Rip Van Winkle: Global Week Ahead

            by John Blank

            Not much looks to influence the markets this week -- until Thursday, when UK elections, an ECB decision and ex-FBI Commissioner James Comey testifies. Don't sleep on these potentially major events regarding market activity.

              BioMarin's (BMRN) Brineura Approved by European Commission

              by Zacks Equity Research

              BioMarin Pharmaceutical Inc. (BMRN) announced that the European Commission has approved Brineura (cerliponase alfa) for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2).

                Universal Display, Hewlett Packard, Regeneron Pharmaceuticals, Sangamo Therapeutics and Puma Biotechnology highlighted as Zacks Bull and Bear of the Day

                by Zacks Equity Research

                Universal Display, Hewlett Packard, Regeneron Pharmaceuticals, Sangamo Therapeutics and Puma Biotechnology highlighted as Zacks Bull and Bear of the Day

                  Teva's Migraine Candidate TEV-48125 Positive in Phase III

                  by Zacks Equity Research

                  Teva Pharmaceutical Industries Limited (TEVA) announced positive top-line results from a phase III study (HALO), evaluating its pipeline candidate, fremanezumab (TEV-48125) for prevention of chronic migraine (CM).

                    Eli Lilly's (LLY) Cancer Drug Cyramza Positive in Phase III

                    by Zacks Equity Research

                    Eli Lilly and Company (LLY) announced positive results from a phase III study evaluating Cyramza for expanded use in combination with docetaxel in patients with locally advanced or unresectable or metastatic urothelial carcinoma.

                      Arpita Dutt headshot

                      3 Hot Biotech Stocks to Buy in June

                      by Arpita Dutt

                      While drug pricing will remain a headline risk, here are a few biotech stocks that have performed well YTD and look well-positioned.

                        Pfizer's Trumenba Vaccine Approved by European Commission

                        by Zacks Equity Research

                        Pfizer Inc. (PFE) announced that its Trumenba vaccine received approval from the European Commission (EC) for active immunization of people aged 10 years and older for the prevention of invasive disease caused by Neisseria meningitidis serogroup B (MenB).

                          Merck's HIV Drug Isentress Gets FDA Approval for Higher Dose

                          by Zacks Equity Research

                          Merck & Co., Inc. (MRK) recently announced that the FDA has approved Isentress HD, a new 1,200 mg once daily dose of its marketed drug Isentress (raltegravir), in combination with other anti-retroviral therapies.

                            Perrigo's (PRGO) Q1 Earnings Beat Estimates, Guidance Intact

                            by Zacks Equity Research

                            Perrigo Company plc (PRGO) reported first-quarter 2017 earnings of $1.05 per share which beat the Zacks Consensus Estimate of 98 cents per share by 7.1%.

                              Will Regeneron's (REGN) Newly Approved Drugs Drive Growth?

                              by Zacks Equity Research

                              We believe approval of new drugs at Regeneron will lessen the company's dependence on Eylea.

                                Sanofi (SNY) Stock Continues to Gain on Key Drug Approvals

                                by Zacks Equity Research

                                After declining in 2016, share price of French pharma giant Sanofi (SNY) has picked up in 2017.

                                  Regeneron Presents Positive Phase II Data on HoFH Candidate

                                  by Zacks Equity Research

                                  Regeneron Pharmaceuticals, Inc. (REGN) presented positive phase II data, evaluating its investigational angiopoietin-like 3 (ANGPTL3) antibody, evinacumab at the National Lipid Association's (NLA) Scientific Sessions.

                                    The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene

                                    by Zacks Equity Research

                                    The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene

                                      Theravance/Mylan Presents Phase III Data on COPD Candidate

                                      by Zacks Equity Research

                                      Theravance Biopharma, Inc. (TBPH) and partner Mylan recently announced the presentation of additional efficacy and safety data from two pivotal phase III studies evaluating its key pipeline candidate, revefenacin (TD-4208).

                                        Arpita Dutt headshot

                                        Biotech Stock Roundup: FDA Nod for Regeneron RA Drug, Amgen Hit by Study Data

                                        by Arpita Dutt

                                        Key highlights in the biotech sector include FDA approval for Regeneron's (REGN) Kevzara and data from Amgen and Celgene.

                                          Merck Presents Phase II Data on Chronic Cough Candidate

                                          by Zacks Equity Research

                                          Merck (MRK) presented data from a phase II study on its pipeline candidate MK-7264 (formerly AF-219) at the American Thoracic Society (ATS) Annual Conference.

                                            Sanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis

                                            by Zacks Equity Research

                                            Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA has approved their pipeline candidate sarilumab to be marketed under the trade name of Kevzara.

                                              Merck's HIV Drug Gets Positive CHMP Opinion for Higher Dose

                                              by Zacks Equity Research

                                              Merck & Co., Inc. (MRK) recently announced that the 600 mg film-coated formulation of its marketed drug, Isentress (raltegravir) in combination with other anti-retroviral therapies, has received positive opinion from CHMP.

                                                Compugen (CGEN) Worth a Look: Stock Adds 10.4% in Session

                                                by Zacks Equity Research

                                                Compugen Ltd. (CGEN) shares rose over 10% in the last trading session.

                                                  Regeneron, Nuance Communications, Waste Management, Waste Connections and Republic Services highlighted as Zacks Bull and Bear of the Day

                                                  by Zacks Equity Research

                                                  Regeneron, Nuance Communications, Waste Management, Waste Connections and Republic Services highlighted as Zacks Bull and Bear of the Day